bausch health cos. inc. - BHC

BHC

Close Chg Chg %
8.33 -0.74 -8.89%

Closed Market

7.59

-0.74 (8.89%)

Volume: 4.78M

Last Updated:

Dec 11, 2024, 3:59 PM EDT

Company Overview: bausch health cos. inc. - BHC

BHC Key Data

Open

$8.09

Day Range

7.42 - 8.12

52 Week Range

3.96 - 11.46

Market Cap

$3.06B

Shares Outstanding

367.80M

Public Float

290.28M

Beta

0.69

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.48

Yield

0.00%

Dividend

$1.00

EX-DIVIDEND DATE

Nov 10, 2010

SHORT INTEREST

N/A

AVERAGE VOLUME

1.42M

 

BHC Performance

1 Week
 
-6.99%
 
1 Month
 
-10.61%
 
3 Months
 
19.94%
 
1 Year
 
4.12%
 
5 Years
 
-75.55%
 

BHC Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 8
Full Ratings ➔

About bausch health cos. inc. - BHC

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

BHC At a Glance

Bausch Health Cos., Inc.
2150 St. Elzéar Boulevard West
Laval, Québec H7L 4A8
Phone 1-514-744-6792 Revenue 8.76B
Industry Pharmaceuticals: Other Net Income -592,000,000.00
Sector Health Technology 2023 Sales Growth 7.792%
Fiscal Year-end 12 / 2024 Employees 20,270
View SEC Filings

BHC Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.336
Price to Book Ratio N/A
Price to Cash Flow Ratio 2.953
Enterprise Value to EBITDA 8.909
Enterprise Value to Sales 2.914
Total Debt to Enterprise Value 0.886

BHC Efficiency

Revenue/Employee 432,017.76
Income Per Employee -29,205.723
Receivables Turnover 4.383
Total Asset Turnover 0.33

BHC Liquidity

Current Ratio 1.301
Quick Ratio 0.942
Cash Ratio 0.224

BHC Profitability

Gross Margin 58.479
Operating Margin 18.271
Pretax Margin -4.454
Net Margin -6.76
Return on Assets -2.232
Return on Equity N/A
Return on Total Capital -2.744
Return on Invested Capital -2.896

BHC Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 104.737
Total Debt to Total Assets 82.622
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 102.368
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Bausch Health Cos. Inc. - BHC

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
8.03B 8.43B 8.12B 8.76B
Sales Growth
-6.67% +5.07% -3.68% +7.79%
Cost of Goods Sold (COGS) incl D&A
3.89B 3.77B 3.58B 3.64B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.83B 1.55B 1.39B 1.26B
Depreciation
180.00M 177.00M 179.00M 187.00M
Amortization of Intangibles
1.65B 1.38B 1.22B 1.08B
COGS Growth
-8.31% -3.21% -5.04% +1.59%
Gross Income
4.13B 4.67B 4.55B 5.12B
Gross Income Growth
-5.08% +12.87% -2.57% +12.67%
Gross Profit Margin
+51.49% +55.31% +55.95% +58.48%
2020 2021 2022 2023 5-year trend
SG&A Expense
2.82B 3.09B 3.15B 3.52B
Research & Development
452.00M 465.00M 529.00M 604.00M
Other SG&A
2.37B 2.62B 2.63B 2.92B
SGA Growth
-6.81% +9.58% +2.10% +11.64%
Other Operating Expense
- - - -
-
Unusual Expense
697.00M 1.19B 66.00M 638.00M
EBIT after Unusual Expense
617.00M 386.00M 1.32B 962.00M
Non Operating Income/Expense
(17.00M) 16.00M 10.00M (24.00M)
Non-Operating Interest Income
13.00M 7.00M 14.00M 26.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
1.53B 1.43B 1.46B 1.33B
Interest Expense Growth
-4.84% -7.04% +2.66% -9.29%
Gross Interest Expense
1.58B 1.49B 1.53B 1.40B
Interest Capitalized
45.00M 60.00M 66.00M 71.00M
Pretax Income
(934.00M) (1.02B) (129.00M) (390.00M)
Pretax Income Growth
+49.16% -9.64% +87.40% -202.33%
Pretax Margin
-11.64% -12.14% -1.59% -4.45%
Income Tax
(375.00M) (87.00M) 83.00M 221.00M
Income Tax - Current - Domestic
8.00M 23.00M 15.00M 21.00M
Income Tax - Current - Foreign
216.00M (74.00M) 256.00M 194.00M
Income Tax - Deferred - Domestic
(9.00M) (20.00M) (14.00M) 21.00M
Income Tax - Deferred - Foreign
(590.00M) (16.00M) (174.00M) (15.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(559.00M) (937.00M) (212.00M) (611.00M)
Minority Interest Expense
1.00M 11.00M 13.00M (19.00M)
Net Income
(560.00M) (948.00M) (225.00M) (592.00M)
Net Income Growth
+68.68% -69.29% +76.27% -163.11%
Net Margin Growth
-6.98% -11.24% -2.77% -6.76%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(560.00M) (948.00M) (225.00M) (592.00M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(560.00M) (948.00M) (225.00M) (592.00M)
EPS (Basic)
-1.5775 -2.6414 -0.6215 -1.6224
EPS (Basic) Growth
+68.94% -67.44% +76.47% -161.05%
Basic Shares Outstanding
355.00M 358.90M 362.00M 364.90M
EPS (Diluted)
-1.5775 -2.6414 -0.6215 -1.6224
EPS (Diluted) Growth
+68.94% -67.44% +76.47% -161.05%
Diluted Shares Outstanding
355.00M 358.90M 362.00M 364.90M
EBITDA
3.14B 3.13B 2.79B 2.86B
EBITDA Growth
-7.78% -0.35% -10.97% +2.84%
EBITDA Margin
+39.11% +37.09% +34.28% +32.71%

Snapshot

Average Recommendation HOLD Average Target Price 8.00
Number of Ratings 8 Current Quarters Estimate 1.122
FY Report Date 12 / 2024 Current Year's Estimate 3.751
Last Quarter’s Earnings 1.142 Median PE on CY Estimate N/A
Year Ago Earnings 3.471 Next Fiscal Year Estimate 4.276
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 6 5 7 7
Mean Estimate 1.12 0.82 3.75 4.28
High Estimates 1.35 0.94 3.98 4.70
Low Estimate 0.90 0.72 3.55 3.28
Coefficient of Variance 12.89 10.12 3.54 11.38

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 5 5 4
UNDERWEIGHT 1 1 1
SELL 1 1 1
MEAN Hold Hold Hold

Bausch Health Cos. Inc. in the News